ModifiedBlue Cross Blue Shield - MassachusettsPolicy 554

Quantitative Electroencephalography as a Diagnostic Aid for Attention-Deficit/Hyperactivity Disorder, Cognitive Impairment, or Autism Spectrum Disorder

Policy governs coverage stance for qEEG (including theta/beta ratio and NEBA system) when used as a diagnostic aid for ADHD, cognitive impairment (eg, dementia), or autism spectrum disorder for Blue Cross Blue Shield Massachusetts members.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyQuantitative Electroencephalography as a Diagnostic Aid for ADHD, Cognitive Impairment, or ASD

Policy CodePolicy 554

Change TypeAdded investigational indications for cognitive impairment and autism spectrum disorderliterature updated through Aug 28, 2024

Effective DateN/A

Next Review DateN/A

Key ActionObtain precertification/preauthorization for inpatient qEEG procedures; outpatient services are not covered for several commercial products.

SourceLink

POLICY UPDATE CHANGES

Indications added for the use of quantitative EEG as a diagnostic aid for cognitive impairment and autism spectrum disorder with investigational policy statements.

Title changed to include newly added indications; indications added for the use of quantitative EEG as a diagnostic aid for cognitive impairment and autism spectrum disorder with investigational policy statements.

Clarified language above code table.

3investigational indications

3 codesCPT codes mentioned

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Precert requiredinpatient authorization

Aug 28, 2024literature review

Coverage Criteria and Policy Statements

Investigational Indications

qEEG is considered investigational for the following diagnostic uses:

ADHD investigational: Quantitative electroencephalographic-based assessment of the theta/beta ratio is considered INVESTIGATIONAL as a diagnostic aid for attention-deficit/hyperactivity disorder.

Includes use of NEBA/theta-beta ratio measurement.

Cognitive impairment investigational: Quantitative electroencephalographic-based assessment is considered INVESTIGATIONAL as a diagnostic aid for cognitive impairment.

Applies to dementia and related disorders.

Autism spectrum disorder investigational: Quantitative electroencephalographic-based assessment is considered INVESTIGATIONAL as a diagnostic aid for autism spectrum disorder.

Applies to ASD diagnostic aid use.

Coverage context and evidence

Summary of evidentiary and policy context influencing coverage decisions

Evidentiary basis for coverage stance: Policy updated with literature through Aug 28, 2024 and adds investigational statements for qEEG as a diagnostic aid for cognitive impairment and autism spectrum disorder; existing policy statement for ADHD remained unchanged.

References include systematic reviews, AAN practice advisory, FDA de novo for an EEG-based ADHD assessment aid, and TEC evaluation.

This evidence review explicitly does not address the use of quantitative EEG (qEEG) in the evaluation of epilepsy or in emergent intraoperative settings. The policy’s scope is limited to qEEG as a diagnostic aid for neurodevelopmental and cognitive disorders rather than seizure localization or intraoperative monitoring.

The policy includes new investigational statements for the use of qEEG as a diagnostic aid in cognitive impairment (eg, dementia) and autism spectrum disorder. These indications were added during the annual review with literature updated through August 28, 2024, and are designated investigational because current evidence is limited and does not establish improved net health outcomes.

Outpatient quantitative EEG is not a covered service for affected commercial products (Commercial Managed Care HMO/POS and Commercial PPO/Indemnity). Precertification/preauthorization is required for inpatient procedures, and outpatient prior authorization requirements vary by product; however, for the outpatient scenarios described in this policy the service is not covered given insufficient evidence of clinical benefit for the covered indications.

Use of qEEG-derived metrics such as the theta/beta ratio to diagnose attention-deficit/hyperactivity disorder (ADHD) is of limited utility. Practice advisories and systematic reviews cited in the policy note inconsistent findings across studies and limited ability of the theta/beta ratio to reliably distinguish individuals with ADHD from controls, supporting the policy’s investigational/not medically necessary stance for standalone diagnostic use.

Coding and Procedure Codes

CPT codes mentioned (informational / considered investigational per policy statement)CPTExperimental

95957	Digital analysis of electroencephalogram (EEG) (eg for epileptic spike analysis).
95812	Electroencephalogram (EEG) extended monitoring; 41-60 minutes
95813	Electroencephalogram (EEG) extended monitoring; greater than 60 minutes

Codes referenced/affected (document notes clarification above code table)mixed

No codes listed

Theta/Beta ratio utility threshold (inv-09)

Validated thresholdNo validated theta/beta ratio threshold established

Guideline findingPractice advisory notes limited utility of the theta/beta ratio to distinguish ADHD from controls (Gloss et al., AAN)

Methodologic variabilityDifferent spectral analysis methods calculate different theta/beta ratios and may affect comparability of values

Implication for interpretationProprietary cutoffs (eg, from commercial systems) are not equivalent to validated population thresholds

Provider Actions, Authorization, and Billing

Prior Authorization

Coverage and Precertification

Precertification/preauthorization is required for inpatient procedures. Outpatient prior authorization requirements vary by product: outpatient quantitative EEG (qEEG) is not a covered service for Commercial Managed Care (HMO and POS) and for Commercial PPO/Indemnity; Medicare PPO likewise does not cover outpatient qEEG. Providers should check product-specific precertification rules when submitting requests.

Precertification required for all inpatient qEEG procedures.
Outpatient qEEG: Commercial Managed Care (HMO and POS) — not covered.
Outpatient qEEG: Commercial PPO/Indemnity — not covered.
Outpatient qEEG: Medicare PPO — not covered.

Denial Risk

Investigational indication denials

Quantitative EEG (qEEG) is considered investigational for certain indications including cognitive impairment and autism spectrum disorder; requests for these investigational indications may be denied. For Commercial members, the policy lists qEEG as investigational for the conditions specified. Providers submitting claims for investigational indications should be prepared for denial and provide supporting evidence if appealing.

Background and Clinical Context

Attention-deficit/hyperactivity disorder (ADHD) is a heterogeneous condition diagnosed clinically by behavioral assessment and standardized rating scales. Quantitative EEG techniques, notably measurement of the theta/beta ratio (ratio of power in the theta [4–7 Hz] band to the beta [13–25 Hz] band at the central midline), have been studied as potential diagnostic aids, including commercial systems (eg, NEBA) that use proprietary cutoffs; however, evidence to date is inconsistent regarding their diagnostic accuracy and impact on patient outcomes.

Definitions and Device Names

Theta/Beta ratio (inv-19)

DefinitionRatio of EEG power in the theta (4–7 Hz) band to the beta (13–25 Hz) band measured at the central midline electrode (Cz).

Frequency bandsTheta: 4–7 Hz; Beta: 13–25 Hz

Measurement locationCentral midline position (Cz) in the international 10–20 EEG system

Use caseUsed by some qEEG systems (eg, NEBA) to estimate likelihood of ADHD based on resting-state EEG

NEBA system (inv-20)

System nameNeuropsychiatric EEG-based ADHD Assessment Aid (NEBA system)

Primary measure

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyQuantitative Electroencephalography as a Diagnostic Aid for ADHD, Cognitive Impairment, or ASD

Policy CodePolicy 554

Change TypeAdded investigational indications for cognitive impairment and autism spectrum disorderliterature updated through Aug 28, 2024

Effective DateN/A

Next Review DateN/A

Key ActionObtain precertification/preauthorization for inpatient qEEG procedures; outpatient services are not covered for several commercial products.

SourceLink

On This Page

Investigational indications include cognitive impairment and autism spectrum disorder (policy updated through Aug 28, 2024).
Investigational indications for qEEG for Commercial members may result in denial of coverage.
Inclusion of CPT/other codes in the policy is informational and does not imply coverage for investigational uses.

Documentation Required

Provider billing and documentation expectations

Providers must report all services using current procedure, revenue, and diagnosis codes, including applicable modifiers. Documentation should support the diagnosis and clinical rationale when qEEG is used as described; expect documentation review when prior authorization is requested or when investigational indications are submitted.

Report services with up-to-date CPT, revenue, and diagnosis codes and modifiers.
Documentation should support the diagnosis and rationale for qEEG use; policy literature reviewed through Aug 28, 2024.
Follow Blue Cross Blue Shield MA medical policy processes when prior authorization for qEEG is requested.

Measures resting theta/beta ratio of the electroencephalogram

Proprietary aspectUses proprietary cutoffs to generate an estimate of likelihood of ADHD

Intended use noted in documentProposed to confirm or support clinical diagnosis or further testing in children and adolescents with clinical suspicion of ADHD

qEEG (inv-21)

DefinitionQuantitative analysis of EEG signals using spectral analysis (eg, fast-Fourier transform), statistical pattern recognition, and derived metrics such as the theta/beta ratio.

TechniquesTransforms time-domain EEG to frequency domain to determine power in frequency bands; computes relative power across delta, theta, alpha, beta bands

Derived metricsIncludes spectral power measures, ratios (eg, theta/beta), and statistical pattern recognition outputs used by commercial systems

Clinical contextInvestigated as an adjunctive diagnostic aid for disorders such as ADHD, cognitive impairment, and autism spectrum disorder but evidence is limited